Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1986 May;64(2):234–242.

Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: II. Reduction of glomerulonephritis.

H C Gunn, B Ryffel
PMCID: PMC1542332  PMID: 3742874

Abstract

Autoimmune (NZB X NZW)F1 mice were treated with the immunosuppressive agent, cyclosporin, and its new derivative (Nva2)-cyclosporin. Both compounds prevented the deposition of immunocomplexes in the kidneys, and the subsequent development of glomerulonephritis and proteinuria in young mice. They also reduced established proteinuria in old mice. Therefore, we feel that both cyclosporin and (Nva2)-cyclosporin may be useful in the treatment of human glomerulonephritis where there is an autoimmune component.

Full text

PDF
234

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borel J. F., Feurer C., Magnée C., Stähelin H. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology. 1977 Jun;32(6):1017–1025. [PMC free article] [PubMed] [Google Scholar]
  2. Cavallo T., Graves K., Granholm N. A. Murine lupus nephritis. Effects of glucocorticoid on circulating and tissue-bound immunoreactants. Lab Invest. 1983 Oct;49(4):476–481. [PubMed] [Google Scholar]
  3. Drachman D. B., Adams R. N., McIntosh K., Pestronk A. Treatment of experimental myasthenia gravis with cyclosporin A. Clin Immunol Immunopathol. 1985 Feb;34(2):174–188. doi: 10.1016/0090-1229(85)90022-4. [DOI] [PubMed] [Google Scholar]
  4. Gelfand M. C., Schur P. H., Asofsky R., Steinberg A. D. Therapeutic studies in NZB/W mice. IV. Effect of combination drug therapy on immune complex deposition. Arthritis Rheum. 1976 Jan-Feb;19(1):43–48. doi: 10.1002/art.1780190107. [DOI] [PubMed] [Google Scholar]
  5. Granelli-Piperno A., Inaba K., Steinman R. M. Stimulation of lymphokine release from T lymphoblasts. Requirement for mRNA synthesis and inhibition by cyclosporin A. J Exp Med. 1984 Dec 1;160(6):1792–1802. doi: 10.1084/jem.160.6.1792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gunn H. C. Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: I. Reduction of autoantibodies. Clin Exp Immunol. 1986 May;64(2):225–233. [PMC free article] [PubMed] [Google Scholar]
  7. Hiestand P. C., Gunn H. C., Gale J. M., Ryffel B., Borel J. F. Comparison of the pharmacological profiles of cyclosporine, (Nva2)-cyclosporine and (Val2)dihydro-cyclosporine. Immunology. 1985 Jun;55(2):249–255. [PMC free article] [PubMed] [Google Scholar]
  8. Howie J. B., Helyer B. J. The immunology and pathology of NZB mice. Adv Immunol. 1968;9:215–266. doi: 10.1016/s0065-2776(08)60444-7. [DOI] [PubMed] [Google Scholar]
  9. Israel-Biet D., Noel L. H., Bach M. A., Dardenne M., Bach J. F. Marked reduction of DNA antibody production and glomerulopathy in thymulin (FTS-Zn) or cyclosporin A treated (NZB X NZW) F1 mice. Clin Exp Immunol. 1983 Nov;54(2):359–365. [PMC free article] [PubMed] [Google Scholar]
  10. Jones M. G., Harris G. Prolongation of life in female NZB/NZW (F1) hybrid mice by cyclosporin A. Clin Exp Immunol. 1985 Jan;59(1):1–9. [PMC free article] [PubMed] [Google Scholar]
  11. Kotzin B. L., Strober S. Reversal of nzb/nzw disease with total lymphoid irradiation. J Exp Med. 1979 Aug 1;150(2):371–378. doi: 10.1084/jem.150.2.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Morris A. D., Esterly J., Chase G., Sharp G. C. Cyclophosphamide protection in NZB/NZW disease. Mechanisms and therapeutic regimens. Arthritis Rheum. 1976 Jan-Feb;19(1):49–55. doi: 10.1002/art.1780190108. [DOI] [PubMed] [Google Scholar]
  13. Moutsopoulos H. M., Boehm-Truitt M., Kassan S. S., Chused T. M. Demonstration of activation of B lymphocytes in New Zealand black mice at birth by an immunoradiometric assay for murine IgM. J Immunol. 1977 Nov;119(5):1639–1644. [PubMed] [Google Scholar]
  14. Neild G. H., Ivory K., Hiramatsu M., Williams D. G. Cyclosporin A inhibits acute serum sickness nephritis in rabbits. Clin Exp Immunol. 1983 Jun;52(3):586–594. [PMC free article] [PubMed] [Google Scholar]
  15. Nussenblatt R. B., Rodrigues M. M., Wacker W. B., Cevario S. J., Salinas-Carmona M. C., Gery I. Cyclosporin a. Inhibition of experimental autoimmune uveitis in Lewis rats. J Clin Invest. 1981 Apr;67(4):1228–1231. doi: 10.1172/JCI110138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Thomson A. W., Whiting P. H., Blair J. T., Davidson R. J., Simpson J. G. Pathological changes developing in the rat during a 3-week course of high dosage cyclosporin A and their reversal following drug withdrawal. Transplantation. 1981 Oct;32(4):271–277. doi: 10.1097/00007890-198110000-00002. [DOI] [PubMed] [Google Scholar]
  17. Vladutiu A. O. Effect of cyclosporine on experimental autoimmune thyroiditis in mice. Transplantation. 1983 May;35(5):518–520. [PubMed] [Google Scholar]
  18. Wick G., Müller P. U., Schwarz S. Effect of cyclosporin A on spontaneous autoimmune thyroiditis of Obese strain (OS) chickens. Eur J Immunol. 1982 Oct;12(10):877–881. doi: 10.1002/eji.1830121014. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES